Interprétation IA fondée sur des extraits vérifiés. Les déclarations de l’entreprise et les limites de couverture restent explicites.
Preuves
Third Sector Insurance Products
Cancer Insurance Aflac Japan pioneered the cancer insurance market in Japan in 1974, and remains the number one provider of cancer insurance in Japan today.
Item 1, Aflac Japan, cancer-insurance market history and current leadership · Dépôt 25/02/2026
At December 31, 2025, Aflac Japan had agreements with approximately 90% of the total number of banks in Japan to sell its products.
Item 1, Aflac Japan, bank distribution agreements · Dépôt 25/02/2026
Since 2008, the Company and Aflac Japan have maintained various commercial and contractual arrangements with Japan Post Holdings and certain of its affiliates.
Related person transactions, Japan Post commercial arrangements since 2008 · Dépôt 19/03/2026
Under these arrangements, affiliates of Japan Post Holdings conduct the sale of Aflac Japan cancer insurance policies and, among other things, provide supplemental support necessary or beneficial to effectuating the sale and servicing of such policies.
Related person transactions, Japan Post distribution and servicing arrangements · Dépôt 19/03/2026
Aflac Japan’s cancer insurance policies issued pursuant to these contractual arrangements constituted approximately 6.7% of Aflac Japan’s earned premium for 2025, representing approximately 3.3% of Aflac Incorporated’s total consolidated earned premium for 2025.
Related person transactions, earned premiums from Japan Post arrangements · Dépôt 19/03/2026
•Persistency remained strong at 93.1% for the year.
2025 selected results, Aflac Japan premium persistency · Dépôt 19/03/2026
The Company's sales associates, brokers and other distribution partners are independent contractors and may sell products of its competitors.
Item 1A, nonexclusive independent distribution · Dépôt 25/02/2026
Since the deregulation of the Japan market in 2001, the number of insurance companies offering stand-alone cancer and medical insurance has increased, intensifying competition.
Item 1, Japanese competitive markets after deregulation · Dépôt 25/02/2026
products. However, given the profitability erosion some major medical carriers are facing in their core lines of business, the Company has seen a more competitive landscape as these carriers seek entry into Aflac's supplemental product segments and leverage their core benefit offerings by bundling and discounting products in order to gain market share.
Item 1, U.S. competitive bundling and discounting · Dépôt 25/02/2026
rolling)
92.8
93.8
(100)
Total benefits and claims (net) / Net earned premiums
62.9
65.8
(290)
Total adjusted expenses / Total adjusted revenues
19.5
19.6
(10)
Pretax adjusted earnings / Total adjusted revenues
35.0
31.8
320
In yen terms, Aflac Japan's net earned premiums were ¥246.7 billion for the quarter, or 3.8% lower than a year ago, mainly due to the impact of a new external reinsurance transaction for WAYS and Tsumitasu as well as limited pay products reaching paid-up status.
First-quarter 2026 Japan operating ratios, persistency and premium movements · Dépôt 29/04/2026
In December 2025, the Company determined that personal information associated with approximately 22.65 million individuals was involved.
Note 13, cyber incident, affected personal information · Dépôt 06/05/2026
The Company believes that the potential amount of loss cannot be reasonably estimated at this time.
Note 13, cyber incident, unquantifiable potential loss · Dépôt 06/05/2026
•Persistency decreased slightly by 10 basis points but remained strong at 79.2%.
2025 selected results, U.S. premium persistency · Dépôt 19/03/2026
Beginning January 2025, the Company implemented a new methodology of calculating persistency rate which excludes annuitizations, premium halving and waiver premium from the terminations; prior periods have not been retroactively adjusted.
Japan operating-ratio methodology, January 2025 persistency definition change · Dépôt 06/08/2026
2025 Selected Results
•Aflac Japan’s sales grew 16.0% for the year reflecting robust sales of Miraito, our latest cancer insurance product, and the continued success of agencies selling Tsumitasu, our repriced life insurance product which offers an asset formation component and options such as nursing care.
2025 selected results, Japanese sales growth and product performance · Dépôt 19/03/2026
We continue to promote awareness for third sector protection to new and younger customers through our innovative first sector product Tsumitasu, which was repriced for new policies effective in September.
Management commentary, Tsumitasu repricing for new policies · Dépôt 04/02/2026
•approval of policy forms and premium rates
Item 1, state regulation, approval of policy forms and premium rates · Dépôt 25/02/2026
As a result, the pretax adjusted profit margin for the Japan segment was 36.7%, compared with 36.0% a year ago.
Full-year 2025 Japan pretax adjusted profit margin comparison · Dépôt 04/02/2026
1,356
1,359
1,501
1,419
1,421
388
370
(4.6)
746
733
(1.7)
1
Corporate and other (1)
(293)
(218)
(425)
32
101
20
(10)
63
(10)
Pretax adjusted earnings
4,819
4,422
4,310
4,945
4,962
1,198
1,101
(8.1)
2,321
2,223
(4.2)
Income taxes (1)
893
808
577
873
954
241
218
(9.5)
458
439
(4.1)
2
Adjusted earnings (2)
3,925
3,614
3,733
4,072
4,008
957
883
(7.7)
1,863
1,784
(4.2)
Reconciling items:
Adjusted net investment gains (losses)
462
447
914
1,495
(375)
(377)
(106)
(1,301)
(3)
Other and non-recurring income (loss)
(73)
1
39
(23)
(54)
—
—
(53)
—
3
Income tax benefit (expense) on items excluded from adjusted earnings (3)
(83)
357
(26)
(101)
67
19
48
119
63
Net earnings
$
4,231
$
4,418
$
4,659
$
5,443
$
3,646
$
599
$
825
37.7
%
$
628
$
1,844
193.6
%
Effective Tax rate
The Company believes that this metric is a key driver of in force levels, which is a key measure of the size of the Company's business and future sources of earnings.
Summary of adjusted results, earnings history and first-half 2026 comparisons · Dépôt 06/08/2026
Financial Statements. Aflac Incorporated and Subsidiaries Consolidated Statements of Earnings Three Months Ended June 30, Six Months Ended June 30, (In millions, except for share and per-share amounts - Unaudited) 2026 2025 2026 2025 Revenues: Net earned premiums, principally supplemental health insurance (1) $ 3,252 $ 3,470 $ 6,562 $ 6,851 Net investment income 984 1,081 1,940 2,036 Net investment gains (losses) (153) (421) (104) (1,384) Other income (loss) 34 30 65 55 Total revenues 4,117 4,160 8,463 7,558 Benefits and expenses: Benefits and claims, excluding reserve remeasurement 1,898 2,047 3,812 4,033 Reserve remeasurement (gains) losses (46) (37) (128) (78) Total benefits and claims, net 1,852 2,010 3,684 3,955 Acquisition and operating expenses: Amortization of deferred policy acquisition costs 218 221 439 437 Insurance commissions 239 251 476 491 Insurance and other expenses 749 804 1,520 1,606 Interest expense 64 52 124 102 Total acquisition and operating expenses 1,270 1,328 2,559 2,636 Total benefits and expenses 3,122 3,338 6,243 6,591 Earnings before income taxes 995 822 2,220 967 Income taxes 170 223 376 339 Net earnings $ 825 $ 599 $ 1,844 $ 628 Net earnings per share: Basic $ 1.64 $ 1.12 $ 3.63 $ 1.16 Diluted 1.63 1.11 3.61 1.16 Weighted-average outstanding common shares used in computing earnings per share (In thousands): Basic 504,123 536,688 508,572 540,676 Diluted 505,578 538,425 510,150 542,629 Cash dividends per share $ .61 $ .58 $ 1.22 $ 1.16 (1) Includes a gain (loss) of an immaterial amount for the three- and six-month periods ended June 30, 2026 and 2025, respectively, related to remeasurement of the deferred profit liability for limited-payment contracts.
Consolidated statements of earnings, first-half 2026 and 2025 · Dépôt 07/08/2026
199 SCHEDULE II CONDENSED FINANCIAL INFORMATION OF REGISTRANT Aflac Incorporated (Parent Only) Condensed Statements of Cash Flows Years ended December 31, (In millions) 2025 2024 2023 Cash flows from operating activities: Net earnings $ 3,646 $ 5,443 $ 4,659 Adjustments to reconcile net earnings to net cash provided from operating activities: Equity in earnings of subsidiaries(1) (3,708) (5,090) (4,418) Cash dividends received from subsidiaries 3,824 4,274 3,410 Other, net (52) (292) (686) Net cash provided (used) by operating activities 3,710 4,335 2,965 Cash flows from investing activities: Fixed maturity securities sold 824 572 547 Fixed maturity securities purchased (772) (695) (345) Other investments sold (purchased) 125 (243) (34) Settlement of derivatives 277 469 693 Additional capitalization of subsidiaries(1) (15) (84) (203) Other, net (58) 0 1 Net cash provided (used) by investing activities 381 19 659 Cash flows from financing activities: Purchases of treasury stock (3,530) (2,800) (2,801) Proceeds from borrowings 1,039 823 0 Principal payments under debt obligations (84) 0 0 Dividends paid to shareholders (1,198) (1,087) (966) Treasury stock reissued 8 14 17 Proceeds from exercise of stock options 7 9 13 Net change in amount due to/from subsidiaries(1) 25 (5) (6) Other, net (20) (7) (17) Net cash provided (used) by financing activities (3,753) (3,053) (3,760) Net change in cash and cash equivalents 338 1,301 (136) Cash and cash equivalents, beginning of period 2,308 1,007 1,143 Cash and cash equivalents, end of period $ 2,646 $ 2,308 $ 1,007 (1) Eliminated in consolidation See the accompanying Notes to Condensed Financial Statements.
Schedule II, parent-only cash flows, financing and distributions · Dépôt 25/02/2026
As of December 31, 2025, Aflac Japan's SMR was 995%, compared with 1,221% at December 31, 2024.
Liquidity and capital resources, Japan SMR at December 2025 and 2024 · Dépôt 25/02/2026
Solvency Margin Ratio (SMR) is solvency margin total divided by one half of the risk total.
Glossary, SMR denominator · Dépôt 25/02/2026
As of December 31, 2025, Aflac Japan estimated the ESR to be above the Company's target range of 170% to 230%.
Liquidity and capital resources, estimated December 2025 Japan ESR · Dépôt 25/02/2026
COMBINED
RISK-BASED CAPITAL (RBC) RATIO(2)
570%
Pay-For-Performance
Compensation Philosophy
OUR COMPENSATION PHILOSOPHY PILLARS
We Pay for Performance.
2025 business highlights, U.S. combined RBC ratio · Dépôt 19/03/2026
Regulatory compliance is determined by a ratio of a company's regulatory total adjusted capital to its authorized control level RBC as defined by the NAIC.
NAIC risk-based capital, regulatory ratio denominator · Dépôt 25/02/2026
(2)The Company calculates its combined RBC ratio to include all U.S.
Business highlights footnote, combined RBC scope · Dépôt 19/03/2026
regulated life insurance entities as if they were a single combined U.S.
Business highlights footnote, combined U.S. regulatory entities · Dépôt 19/03/2026
RBC entity net of intercompany items related to capital resources and risk.
Business highlights footnote, combined RBC intercompany netting · Dépôt 19/03/2026
Purpose
uncommitted bilateral
364 days
December 4, 2026
$100 million
$0 million
The rate quoted by the bank and agreed upon at the time of borrowing
Up to 3 months
None
General corporate purposes
unsecured revolving
5 years
May 13,
2030, or the date commitments are terminated pursuant to an event of default
¥100.0 billion
¥0.0 billion
A rate per annum equal to, at the Company's option, either (a) Tokyo Interbank Market Rate (TIBOR) plus an applicable margin or (b) an alternative TIBOR based on the rate offered by the agent to major banks in yen for the applicable period plus an applicable margin
No later than
May 14, 2030
.28% to .45%, depending on the Parent Company's debt ratings as of the date of determination
Liquidity and capital resources, undrawn yen revolving facility · Dépôt 07/08/2026
dollar-denominated borrowings or three-month TIBOR plus 68 basis points per annum for Japanese yen-denominated borrowings
No later than December 2, 2026
None
General corporate purposes
(1) Intercompany credit agreement
The Company was in compliance with all of the covenants of its notes payable and lines of credit at June 30, 2026.
Notes payable and credit facilities, June 2026 covenant compliance · Dépôt 07/08/2026
Investment exposures that individually exceeded 10% of shareholders' equity were as follows: June 30, 2026 December 31, 2025 (In millions) Credit Rating Amortized Cost Fair Value Credit Rating Amortized Cost Fair Value Japan National Government(1) A+ $29,714 $24,612 A+ $32,618 $28,434 (1) Japan Government Bonds (JGBs) or JGB-backed securities 16 Net Investment Gains and Losses Information regarding pretax net investment gains and losses was as follows: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2026 2025 2026 2025 Net investment gains (losses): Sales and redemptions: Fixed maturity securities available-for-sale: Gross gains from sales $ 0 $ 5 $ 1 $ 119 Gross losses from sales (837) (98) (978) (333) Foreign currency gains (losses) 599 79 725 240 Other investments: Gross gains (losses) from sales and redemptions 0 11 (2) 12 Total sales and redemptions (238) (3) (254) 38 Equity securities 87 98 73 37 Impairment losses (11) (6) (35) (6) Credit losses: Fixed maturity securities held-to-maturity 0 0 1 0 Commercial mortgage and other loans (76) (61) (126) (114) Loan commitments (1) 2 1 0 Reinsurance recoverables and other 0 1 (14) 1 Total credit losses (77) (58) (138) (113) Derivatives and other: Derivative gains (losses) (134) 23 (229) (22) Foreign currency gains (losses) 220 (475) 479 (1,318) Total derivatives and other 86 (452) 250 (1,340) Total net investment gains (losses) $ (153) $ (421) $ (104) $ (1,384) In the three-month period ended June 30, 2026, the Company did not recognize impairment losses on real estate owned (REO) properties.
Note 3, investment concentration, realized investment and credit losses · Dépôt 07/08/2026
Transitional Real Estate Loans (In millions) 2026 2025 2024 2023 2022 Prior Total Loan-to-Value Ratio: 0%-59.99% $ 0 $ 0 $ 0 $ 0 $ 141 $ 157 $ 298 60%-69.99% 0 0 0 0 324 304 628 70%-79.99% 0 0 0 14 515 457 986 80% or greater 65 0 0 0 349 1,018 1,432 Total $ 65 $ 0 $ 0 $ 14 $ 1,329 $ 1,936 $ 3,344 Current-period gross writeoffs: $ 0 $ 0 $ 0 $ 0 $ 8 $ 0 $ 8 Commercial Mortgage Loans (In millions) 2026 2025 2024 2023 2022 Prior Total Weighted-Average DSCR Loan-to-Value Ratio: 0%-59.99% $ 35 $ 11 $ 0 $ 31 $ 0 $ 1,061 $ 1,138 2.80 60%-69.99% 13 20 0 0 0 77 110 1.91 70%-79.99% 0 0 0 0 0 72 72 1.45 80% or greater 0 0 12 0 0 36 48 0.87 Total $ 48 $ 31 $ 12 $ 31 $ 0 $ 1,246 $ 1,368 2.59 Weighted Average DSCR 1.90 1.83 1.09 2.74 0.00 2.65 Current-period gross writeoffs: $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 26 Middle Market Loans (In millions) 2026 2025 2024 2023 2022 Prior Revolving Loans Total Credit Ratings: BBB $ 73 $ 13 $ 61 $ 22 $ 0 $ 94 $ 6 $ 269 BB 269 355 506 114 296 774 66 2,380 B 49 291 124 46 232 628 45 1,415 CCC 0 25 3 0 34 273 26 361 CC 6 5 2 0 10 81 8 112 C and lower 0 0 0 0 0 53 7 60 Total $ 397 $ 689 $ 696 $ 182 $ 572 $ 1,903 $ 158 $ 4,597 Current-period gross writeoffs: $ 0 $ 0 $ 0 $ 0 $ 0 $ 11 $ 0 $ 11 Other Loans (In millions) 2026 2025 2024 2023 2022 Prior Revolving Loans Total Credit Ratings: A $ 20 $ 0 $ 0 $ 0 $ 60 $ 0 $ 0 $ 80 AA 0 0 0 0 8 3 0 11 BBB 81 37 257 0 24 24 0 423 BB 0 0 0 64 0 0 0 64 Total $ 101 $ 37 $ 257 $ 64 $ 92 $ 27 $ 0 $ 578 Current-period gross writeoffs: $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 Other Investments The table below presents the composition of the carrying value for other investments as of the periods presented.
Note 3, real-estate and middle-market loan quality and writeoffs · Dépôt 07/08/2026
Currently, when the Company's fixed maturity securities mature, the proceeds may be reinvested at a yield below that required for the accretion of policy benefit liabilities on policies issued in earlier years.
Liquidity and capital resources, reinvestment yields versus liability accretion · Dépôt 07/08/2026
Common stock - issued:
Balance, beginning of period
1,357,909
1,356,763
Exercise of stock options and issuance of restricted shares
1,027
Balance, end of period
1,358,830
1,357,790
Treasury stock:
Balance, beginning of period
839,219
806,799
Purchases of treasury stock:
Share repurchase program
16,413
Dispositions of treasury stock:
Shares issued to AFL Stock Plan
(328)
(366)
(42)
(41)
(167)
(226)
Balance, end of period
856,573
822,981
Shares outstanding, end of period
502,257
534,809
Share Repurchase Program: During the first six months of 2026, the Company repurchased 17.5 million shares of its common stock for $2.0 billion as part of its share repurchase program.
Note 10, outstanding shares and first-half 2026 repurchases · Dépôt 07/08/2026
(In millions, except for per-share amounts) 2025 2024 2023 Impact on earnings from continuing operations $ 82 $ 72 $ 79 Impact on earnings before income taxes 82 72 79 Impact on net earnings 65 57 62 Impact on net earnings per share: Basic $ .12 $ .10 $ .10 Diluted .12 .10 .10 175 Item 8.
Note on share-based compensation, reported 2025 expense · Dépôt 25/02/2026
As part of its overall corporate strategy, the Company has committed up to $400 million to Aflac Ventures, LLC (Aflac Ventures) as opportunities emerge, of which approximately $230 million has been deployed as of June 30, 2026.
Investing activities, Aflac Ventures commitment and deployment · Dépôt 07/08/2026
GAAP ROE - Net earnings1
12.3
4.7
Impact of excluding unrealized foreign currency translation gains (losses)
(2.2)
(0.8)
Impact of excluding unrealized gains (losses) on securities and derivatives
(0.2)
Impact of excluding effect of changes in discount rate assumptions
4.0
0.7
Impact of excluding pension liability adjustment
—
—
Impact of excluding AOCI
0.9
(0.3)
U.S.
First-half ROE reconciliation, GAAP return on average shareholders' equity · Dépôt 06/08/2026
GAAP ROE - less AOCI
13.2
4.4
Differences between adjusted earnings and net earnings2
(0.4)
8.7
Adjusted ROE - reported
12.8
13.1
Impact of excluding gains (losses) associated with foreign currency remeasurement3
3.9
3.0
Adjusted ROE, excluding foreign currency remeasurement
16.7
16.1
1 U.S.
First-half ROE reconciliation, adjusted return measures · Dépôt 06/08/2026
•Adjusted return on equity excluding foreign currency remeasurement is annualized adjusted earnings divided by average shareholders’ equity, excluding both accumulated other comprehensive income and the cumulative (beginning January 1, 2021) foreign currency gains/losses associated with i) foreign currency remeasurement and ii) sales and redemptions of invested assets.
Non-GAAP measures, adjusted ROE excluding currency remeasurement definition · Dépôt 06/08/2026
Miller 300 % Audrey Boone Tillman 325 % 52 AFLAC INCORPORATED EXECUTIVE COMPENSATION LTI Performance Metrics The PBRS will vest based on the Company’s achievement on a combination of these measures—AROE, RBC, SMR/ESR —for the cumulative three-year performance period beginning January 1, 2025 and ending December 31, 2027.
Executive compensation, granted 2025–2027 performance award metrics · Dépôt 19/03/2026
74 Performance-Based Restricted Stock In 2026, the Company granted 289 thousand shares of performance-based stock, which are contingent on the achievement of the Company's financial performance metrics and certain market conditions.
Note 11, actual 2026 performance-based stock grants · Dépôt 07/08/2026
Actual performance, including modification for relative total shareholder return, may result in the ultimate award of 0% to 200% of the initial number of performance-based restricted stock issued, with the potential for no award if the Company's performance goals are not achieved.
Note 11, performance-award payout range and relative shareholder return · Dépôt 07/08/2026
Tillman are retirement-eligible under the terms of the Company’s equity agreements and each will vest in all equity awards granted at least one year before the date his or her employment terminates (subject to satisfaction of performance goals).
Termination benefits, retirement eligibility and equity vesting provisions · Dépôt 19/03/2026
In particular: •a substantial majority of our Board members are independent; •the Audit and Risk, Compensation, and Corporate Governance Committees all comprise independent Directors; •the Company has a Lead Non-Management Director with significant responsibilities, as described below; •the Non-employee Directors meet at each regularly scheduled Board meeting in executive session without management present; •the Corporate Governance Committee oversees and manages the annual assessment of Board performance, which includes consideration of the effectiveness of our Board leadership structure; •our shareholders have several avenues to make their views known, including the ability to amend the Bylaws of the Company, to call a special meeting of shareholders and to include director nominations in our proxy materials; and •members of our management team and/or independent Directors proactively engage on a year-round basis with our shareholders to understand their perspectives on our business, strategy, management, Board, and governance practices.
Corporate governance, independent committees and shareholder rights · Dépôt 19/03/2026
Total for PEO(1)
Actually Paid to
PEO(2)(7)
Average Summary
Total for Non-PEO
NEOs(3)
Actually Paid to
Non-PEO
NEOs(2)(9)
Value of Initial Fixed $100
Investment Based On:
Income*(5)
Equity(5)(6)(7)
Peer Group Total
Return(4)
$25,033,687
$38,988,251
$6,833,991
$9,579,272
$278.50
$201.00
$3,646
$19,268,254
$36,602,092
$4,853,760
$7,733,169
(8)
$255.62
$189.87
$5,443
17.7
$20,703,253
$40,403,440
$6,201,143
$8,477,924
(8)
$199.58
$157.83
$4,659
14.2
$15,776,291
$32,797,790
$5,168,408
$8,807,464
$170.03
$150.82
$4,418
13.9
$15,728,233
$27,847,653
In light of the fact that the shares acquired by the Trust, like all Aflac Incorporated shares of Common Stock, are eligible for 10-for-1 voting rights, having been held for 48 consecutive months, the Shareholders Agreement further provides for voting restrictions that effectively limit the trustee’s voting rights to no more than 20% of the voting rights in the Company and further restrict the trustee’s voting rights with respect to certain change in control transactions.
Ownership arrangements, time-phased voting rights and trustee restrictions · Dépôt 19/03/2026
DANIEL P. AMOS, 74
Chairman and
Chief Executive Officer,
Director Since 1983
Committees: E, FI
W.
Director summary, combined chairman and CEO roles · Dépôt 19/03/2026
The Company's systems were not affected by ransomware, and the Company remained able to serve its policyholders and underwrite policies, review claims, and otherwise service customers as usual.
Note 13, cyber incident, continued policyholder service · Dépôt 06/05/2026
•Sales of nearly $1.6 billion were up 3.0%.
2025 selected results, U.S. new sales · Dépôt 19/03/2026
There were no material findings in any of the NDOI and NYSDFS final examination reports.
State regulation, completed examination findings · Dépôt 25/02/2026
(In thousands of shares) Shares Weighted-Average Grant-Date Fair Value Per Share Restricted stock at December 31, 2025 1,867 $ 86.15 Granted in 2026 928 119.68 Canceled in 2026 (18) 101.26 Vested in 2026 (1,093) 75.39 Restricted stock at June 30, 2026 1,684 $ 102.84 As of June 30, 2026, total compensation cost not yet recognized in the Company's consolidated financial statements related to restricted stock was $82 million, of which $42 million (1.4 million shares) was related to performance-based restricted stock.
Note 11, restricted-share activity and unrecognized compensation cost · Dépôt 07/08/2026
•The company returned $1.3 billion to shareholders, consisting of $983 million in share repurchase and $309 million in dividends.
Second-quarter 2026 actual buybacks and dividends · Dépôt 06/08/2026
The initial report on the ESR will be issued as of March 31, 2026, which is Aflac Japan's 2025 fiscal year-end.
Japan solvency regime transition, initial ESR reporting date · Dépôt 25/02/2026
The decrease in annualized premiums in force in Japanese yen of 2.5% in 2025 and 3.0% in 2024 was driven primarily by limited-pay products reaching premium paid-up status.
Japan premiums in force, limited-pay policies reaching paid-up status · Dépôt 25/02/2026
